Study design: Double-blind, randomised, multicentre study.
Objectives: Efficacy and tolerability of propiverine extended-release (ER) compared with immediate-release (IR) were evaluated in patients with proven neurogenic detrusor overactivity (NDO).
Setting: Six Spinal Cord Injury Units located in Austria, Germany and Romania.
Methods: Propiverine ER 45 mg s.i.d. or IR 15 mg t.i.d. were administered in patients with proven NDO. Outcomes were assessed at baseline (V1), and after 21 days of treatment (V2): Reflex volume served as primary, leak point volume and maximum detrusor pressure as secondary efficacy outcomes, treatment-related adverse events as tolerability outcomes.
Results: Sixty-six patients with proven NDO were enrolled. Reflex volume (ml) increased significantly in the IR (V1: 100.9, V2: 202.9) and in the ER (V1: 89.8, V2: 180.3) group, no significant intergroup difference. Leak point volume increased, and maximum detrusor pressure decreased significantly in both groups, no significant intergroup differences. The percentage of patients presenting with incontinence was reduced by 14% in the IR and by 39% in the ER group, the difference is significant. Treatment-related adverse events manifested in 42 and 36% following propiverine IR and ER, respectively.
Conclusion: The urodynamic efficacy outcomes demonstrated both galenic formulations to be equieffective. However, following propiverine ER 45 mg s.i.d. higher continence rates compared with propiverine IR 15 mg t.i.d. were achieved, possibly indicative of more balanced plasma-levels. A slight tendency for superior tolerability outcomes of propiverine ER compared with IR was demonstrated.
Sponsorship: The study was sponsored by an unrestricted educational grant of APOGEPHA Arzneimittel GmbH, Dresden, Germany.
Written by:
Stöhrer M, Mürtz G, Kramer G, Warnack W, Primus G, Jinga V, Manu-Marin A, Calomfirescu N, Strugala G. Are you the author?
Department of Urology and Paediatric Urology, Universität Essen, Essen, Germany.
Reference: Spinal Cord. 2013 Jan 22. Epub ahead of print.
doi: 10.1038/sc.2012.174
PubMed Abstract
PMID: 23338657
UroToday.com Overactive Bladder (OAB) Section
